PMID- 34509354
OWN - NLM
STAT- MEDLINE
DCOM- 20220419
LR  - 20220419
IS  - 0219-3108 (Electronic)
IS  - 1015-9584 (Linking)
VI  - 45
IP  - 5
DP  - 2022 May
TI  - Clinical analysis of systemic chemotherapy combined with microwave ablation in 
      the treatment of lung cancer.
PG  - 1107-1112
LID - S1015-9584(21)00515-7 [pii]
LID - 10.1016/j.asjsur.2021.08.013 [doi]
AB  - OBJECTIVE: To explore the therapeutic effect of systemic administration combined 
      with microwave ablation (MWA) under computed tomography (CT) and fiberoptic 
      bronchoscope for treating lung cancer. METHODS: Sixty-six patients with advanced 
      lung cancer admitted to our hospital from February 2019 to February 2020 were 
      collected and divided into control group and experimental group with 33 patients 
      in each group. The control group was treated with systemic administration, and 
      the experimental group was treated with systemic administration combined with MWA 
      under CT and fiberoptic bronchoscope. Overall response rate (ORR), adverse events 
      (AEs) during treatment, and survival analysis were used to evaluate the curative 
      effect of lung cancer treatment in each group. RESULTS: MWA under CT and 
      fiberoptic bronchoscope could safely remove the cancerous tissues by point 
      burning without destroying the adjacent normal tissues with high success rate. 
      The ORR of the control group was 24.4%, and that of the experimental group was 
      63.6%, which was better than the control group. The AEs occurred during treatment 
      in each group were of level 1 or level 2, and no serious life-threatening AEs 
      occurred. Progression-free survival (PFS) time and overall survival (OS) time in 
      the experimental group were both longer than those in the control group. Patients 
      treated with MWA had a lower risk of disease progression and death than those 
      treated with systemic administration alone. CONCLUSION: The treatment of lung 
      cancer using systemic administration combined with MWA under CT and fiberoptic 
      bronchoscope is more effective than using systemic administration alone, which 
      can be promoted in clinical treatment.
CI  - Copyright (c) 2021. Published by Elsevier Taiwan LLC.
FAU - Feng, Kan
AU  - Feng K
AD  - Department of Thoracic Surgery, The First Hospital of Fuyang Hangzhou, Hangzhou, 
      Zhejiang Province, 3114000, China. Electronic address: kanfengeng@163.com.
FAU - Lu, Yong
AU  - Lu Y
AD  - Department of Thoracic Surgery, The First Hospital of Fuyang Hangzhou, Hangzhou, 
      Zhejiang Province, 3114000, China.
LA  - eng
PT  - Journal Article
DEP - 20210909
PL  - Netherlands
TA  - Asian J Surg
JT  - Asian journal of surgery
JID - 8900600
SB  - IM
MH  - *Catheter Ablation
MH  - Combined Modality Therapy
MH  - Humans
MH  - *Lung Neoplasms/surgery
MH  - Microwaves/therapeutic use
MH  - *Radiofrequency Ablation
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Clinical analysis
OT  - Fiberoptic bronchoscope
OT  - Lung cancer
OT  - Microwave ablation
OT  - Systemic administration
OT  - computed tomography
COIS- Declaration of competing interest The authors declare that they have no potential 
      conflicts of interest.
EDAT- 2021/09/13 06:00
MHDA- 2022/04/20 06:00
CRDT- 2021/09/12 20:36
PHST- 2021/05/19 00:00 [received]
PHST- 2021/08/08 00:00 [revised]
PHST- 2021/08/18 00:00 [accepted]
PHST- 2021/09/13 06:00 [pubmed]
PHST- 2022/04/20 06:00 [medline]
PHST- 2021/09/12 20:36 [entrez]
AID - S1015-9584(21)00515-7 [pii]
AID - 10.1016/j.asjsur.2021.08.013 [doi]
PST - ppublish
SO  - Asian J Surg. 2022 May;45(5):1107-1112. doi: 10.1016/j.asjsur.2021.08.013. Epub 
      2021 Sep 9.